IMMP - Immutep reports good safety from first five patients in efti triple combination study

Immutep (NASDAQ:IMMP) announces the first five patients have been treated in the INSIGHT-003 study. Shares up 2.2% premarket at $3.30. No additional safety signals have been observed in the study which is the first time a triple combination therapy consisting of eftilagimod alpha (“efti”) and an existing approved standard of care combination of chemotherapy (carboplatin) and an anti-PD-1 therapy has been administered. The study will continue to recruit up to 20 patients with various solid tumors and additional results are expected in calendar year 2022. The trial will assess the safety, tolerability and initial efficacy of the combination.

For further details see:

Immutep reports good safety from first five patients in efti triple combination study